The time is now: expedited HIV differentiated service delivery during the COVID‐19 pandemic
Open accessThe DOI matches its Crossref record.
Abstract
At its core, differentiated service delivery (DSD) for HIV is centred around clients' needs and expectations and relieving unnecessary burdens on the health system [1]. In the 2016 World Health Organization (WHO) antiretroviral therapy (ART) guidelines, it was acknowledged that adaptations to the delivery of HIV services were necessary to achieve the "treat all" recommendation [2]. This transition from a "one-size-fits-all approach" to DSD means modifying the location, frequency and package of services as well as the cadre providing services, considering the clinical needs, specific population and the context including urbanicity, stability of context (for example high migration, conflict or pandemic) and type of HIV epidemic [2-4]. Existing global and national policies around DSD for HIV can be leveraged during the COVID-19 pandemic to play a critical role in supporting uninterrupted ART and reducing avoidable contact with health facilities, thereby supporting health systems to focus on COVID-19. Recent statements from The Global Fund for HIV, Tuberculosis and Malaria (Global Fund), the Global Network of People Living with HIV (GNP+), UNAIDS, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and the WHO all endorse leveraging components of DSD for people living with HIV (PLHIV) during the COVID-19 pandemic [4-9]. The time is now to accelerate access to DSD for all PLHIV. We acknowledge that accelerating access requires capacity in addition to policy decisions. Scaling up the provision of longer ART refills is highly dependent on supply chains that may be currently under threat. There are concerns of constraints in ART production in the coming months as a result of the lockdown in India; with the Global Fund currently rating the operational risk assessment as "moderate" [10]. The global supply situation is being closely monitored and coordinated by partners with PEPFAR tempering language around the duration of multi-month dispensing to ensure continuity of care [11, 12]. Countries are being encouraged to submit orders well in advance, adjust supply plans for longer leads times, distribute stock to clinics rather than holding it centrally and transparently communicate stock levels by regimen at the national and provincial level to support planning [11, 13, 14]. Concerns regarding ritonavir-boosted lopinavir availability pre-dated COVID-19, and plans to transition to other antiretrovirals are being accelerated in countries with large numbers of patients on this regimen [15]. With many sub-Saharan countries' forecasts increasing numbers of PLHIV on a Dolutegravir (DTG)-based first-line regimen and a slower enrolment and transition to DTG regimens than predicted, this stock may be less threatened than the Efavirenz (EFV)-based regimens. This further strengthens the need for supporting patients to immediately transition to DTG regimens without requiring additional clinical monitoring visits to health facilities. There is precedent for expediting DSD approaches during times of emergency. During the 2014-2015 Ebola outbreak, Guinea started providing PLHIV with 6-month ART refills – both to ensure that patients were not exposed to Ebola by visiting health facilities and because many health facilities closed [16, 17]. In Sierra Leone, peers started collecting and distributing ART refills to patients' homes or from community meeting points [18]. In response to conflict in the Central African Republic in 2015, patients were provided with 6-month refills distributed by lay healthcare workers from decentralized peripheral health facilities [19]. More recently, in 2019 during armed conflict in the Cabo del Gado province of Mozambique, mobile clinics provided outreach and ART refills within communities [20]. At a time when we lack data on the clinical outcomes of PLHIV co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and in the context of resource constrained public health systems where millions of PLHIV are not on treatment or virally suppressed, we need to take every precaution possible to avoid SARS-CoV-2 co-infection. DSD provides the necessary tools to take these precautions; most importantly by adapting the "when" and "where" through reducing the frequency of visits and enabling ART refills outside of health facilities [1, 21]. A number of adaptations to DSD are outlined below and should be considered in addition to implementation of critical infection control and physical distancing measures that are recommended for everyone. For those clinically stable on ART but not yet enrolled in a DSD model, we must accelerate access by revising eligibility criteria and ensuring those with one suppressed viral load or evidence of treatment success after six months on treatment are immediately enrolled. Out-of-facility models for ART refills should be prioritized over facility-based models. Refills should be extended to a minimum of three months with 6-month refills permitted wh
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dorward, J., Khubone, T., Gate, K., Ngobese, H., Sookrajh, Y., Mkhize, S., Jeewa, A., Bottomley, C., Lewis, L., Baisley, K., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30359-3 · Cited by 300
Grimsrud, A., & Wilkinson, L. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25704 · Cited by 104
“In April 2020, we outlined how DSD for HIV treatment should be expedited and adapted in response to COVID-19 – by reducing the frequency of visits and enabling ART refills outside of health facilities, expanding who was eligible for DSD for HIV treatment and supporting testing and rapid, community-based initiation for…”
MethodSelf-citationFeldacker, C., Mugwanya, R., Irongo, D., Kathumba, D., Chiwoko, J., Kitsao, E., Sippell, K., Wasunna, B., Jonas, K., Samala, B., et al. (2023) · JMIR Formative Research · doi:10.2196/48671 · Cited by 14
Bisnauth, M. A., Coovadia, A., Kawonga, M., & Vearey, J. (2022) · Global Health Action · doi:10.1080/16549716.2022.2100602 · Cited by 9
“This could reduce the risk of exposure to COVID-19 where vulnerabilities are amplified for individuals who are often turned away at facilities [35,36,37,39,38].”
Background
Metadata
- Authors
- Wilkinson, L., & Grimsrud, A.
- Venue
- Journal of the International AIDS Society
- Publisher
- Wiley
- Published
- 2020-05
- Volume
- 23
- Issue
- 5
- Pages
- e25503-e25503
- ISSN
- 1758-2652 (ISSN-L)
- OpenAlex
- W3020227720
- Cited by
- 96
- References
- 0
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.